                          AIDS Daily Summary
                            March 31, 1995


The Centers for Disease Control and Prevention (CDC) National AIDS
Clearinghouse makes available the following information as a public
service only. Providing this information does not constitute endorsement
by the CDC, the CDC Clearinghouse, or any other organization. Reproduction
of this text is encouraged; however, copies may not be sold, and the CDC
Clearinghouse should be cited as the source of this information.
Copyright 1995, Information, Inc., Bethesda, MD


************************************************************
"AIDS Drug AZT Most Effective Early On, Study Finds"
"AIDS Exhibit"
"Poz Magazine Sale Set"
"AIDS Activists Urge Yeltsin Not to Sign New Law"
"Work Starts on Home for AIDS Patients"
"Sacked Bishop Attacks Encyclical for Ignoring AIDS"
"AIDS Research Policy"
"Crystal Structure and Function of the Isoniazid Target of 
Mycobacterium Tuberculosis"
"Conjunctival Squamous-Cell Carcinoma Associated with HIV 
Infection in Kampala, Uganda"
"Artificial Insemination by Donor"
************************************************************

"AIDS Drug AZT Most Effective Early On, Study Finds"
Reuters (03/30/95)
     According to Clive Loveday, Steve Kaye and colleagues at 
University College in London, AZT is most effective against HIV 
in the first few days of treatment.  The doctors reported their 
findings in Friday's issue of the journal Lancet.  The virus 
appeared to recover within six months but did not demonstrate 
consistent mutations into other forms.  Kaye said the study was 
especially significant for treating pregnant women because, "If 
you gave the drug very early in pregnancy it might not work as 
effectively...given that most transmission seems to occur fairly 
late in pregnancy."
      
"AIDS Exhibit"
Washington Times (03/31/95) P. A2;  Pinkerton, Jennifer
     The Museum of Science and Industry is sponsoring the first 
permanent AIDS exhibit,  entitled "AIDS, the War Within," to 
educate children about the disease.  Included in the exhibit are 
the depiction of doctors and scientists--who are fighting 
AIDS--as superheroes, and a touch-screen video game called "Be an
Epidemiologist," which allows children to explore how the disease
is transmitted.  The Centers for Disease Control and Prevention 
and AIDS awareness groups were among those who organized and 
worked on the exhibit.
      
"Poz Magazine Sale Set"
New York Times (03/31/95) P. D2
     Poz, a New York magazine about AIDS and HIV, will be sold to a 
group that includes Out Publishing Inc., the publisher of Out 
magazine.  Poz publisher Sean Strub will act as chairman of the 
new entity, Poz Publishing, and executive editor of Poz.
      
"AIDS Activists Urge Yeltsin Not to Sign New Law"
Reuters (03/30/95);  Stephenson, Nigel
     The AESOP sexual health information center in Moscow said on 
Thursday that it had written to Russian President Boris Yeltsin 
in regard to a controversial new law due to be signed on Friday. 
The measure would require foreigners planning to stay in Russia 
for more than three months to prove that they are HIV-free.  It 
would also mandate HIV testing for workers in certain 
professions.  AESOP Chairman Kevin Gardner said, "As we have 
discovered in the fight against AIDS around the world, it is not 
laws that stop AIDS but concrete actions, programmes that are 
geared toward helping people learn about AIDS and how not to get 
it."
      
"Work Starts on Home for AIDS Patients"
St. Louis Post-Dispatch (03/30/95) P. 1B;  Volland, Victor
     An interfaith outreach program known as Doorways is renovating a 
100-year-old building in St. Louis to serve as a housing facility
for people in the advanced stages of AIDS.  The renovation 
project, which began on Wednesday, is estimated to cost about $2 
million.  The 36-bed facility, expected to be completed by 
November, will offer residents a variety of medical and social 
services.  The hospice-style center will be the only facility in 
Missouri licensed as a residential care facility for people with 
AIDS.  Doorways currently operates apartments and other 
independent living units for people with AIDS, and also pays rent
and mortgage subsidies to roughly 125 other HIV or AIDS patients.
Lynne M. Cooper, executive director of Doorways, says the new 
facility will allow residents to live in safe, clean surroundings
and reduce unnecessary hospitalizations resulting from inadequate
housing.
      
"Sacked Bishop Attacks Encyclical for Ignoring AIDS"
Reuters (03/30/95)
     Sacked French bishop Jacques Gaillot reproached Pope John Paul's 
encyclical, Evangelium Vitae (The Gospel of Life), for not 
mentioning AIDS in its defense of life.  This encyclical contains
the strongest opposition to abortion, euthanasia and other 
medical practices which affect life.  Because Gaillot lobbied for
condom use to prevent AIDS and other ideas which defy Vatican 
doctrine, he was transferred to a diocese in southern Algeria.
      
"AIDS Research Policy"
Science (03/10/95) Vol. 267, No. 5203, P. 1405;  William E. Paul
     Activist Larry Kramer's recent criticism represents an inaccurate
description of the role and the actions of the National 
Institutes of Health's (NIH) Office of AIDS Research (OAR), 
writes OAR director William E. Paul in a letter to the editors of
Science.  Contrary to Kramer's claims that the OAR has abdicated 
its responsibility for the preparation of a comprehensive plan to
guide NIH-sponsored AIDS research, such a plan was completed 
within weeks of Paul's appointment as director.  The plan formed 
the basis for the development of the fiscal year 1996 budget, 
which is now being considered by Congress.  According to Paul, 
Kramer also seems to be unaware of the high priority that the OAR
has placed on primate research.  His view that drug development 
would be greatly accelerated by the use of the simian 
immunodeficiency/macaque model is not supported by advice the OAR
has received from senior scientists in the pharmaceutical 
industry.  Finally, Paul states that Kramer's contention that 
U.S. taxpayers "are getting a rotten value for their money" is 
untrue.  NIH-sponsored research has contributed immeasurably to 
the health of the American people, he says.  The OAR is confident
that a new and effective course in being charted for the future 
of NIH OAR research, concludes Paul.
      
"Crystal Structure and Function of the Isoniazid Target of 
Mycobacterium Tuberculosis"
Science (03/17/95) Vol. 267, No. 5204, P. 1638;  Dessen, Andrea; 
Quemard, Annaik;  Blanchard, John S. et al.
     Although isoniazid has been a first-line chemotherapeutic in the 
treatment of tuberculosis (TB), it is ineffective against newly 
emergent strains of Mycobacterium tuberculosis, which kill 70 to 
90 percent of AIDS patients who develop TB.  Resistance to the 
drug in Mycobacterium tuberculosis, however, can be mediated by 
the substitution of alanine for serine 94 in the InhA protein, 
the drug's principal target.  Kinetic analyses indicate that 
isoniazid resistance is the result of a reduced affinity of the 
mutant protein for nicotinamide adenine dinucleotide (NADH).  The
three-dimensional structures of wild-type and mutant InhA 
demonstrate that drug resistance is directly related to a 
perturbation in the hydrogen-bonding network that stabilizes NADH
binding.
      
"Conjunctival Squamous-Cell Carcinoma Associated with HIV 
Infection in Kampala, Uganda"
Lancet (03/18/95) Vol. 345, No. 8951, P. 695;  Ateenyi-Agaba, C.
     C. Ateenyi-Agaba reports an increase in the number of 
conjunctival cancers in patients attending a Ugandan hospital.  
The finding is supported by data from the Kampala Cancer 
Registry, which shows that the incidence of conjunctival 
squamous-cell carcinoma remained at six per million per year 
between 1970 and 1988, but has since increased six-fold.  
Seventy-five percent of the 48 patients with conjunctival growths
tested HIV-positive, compared to a 19 percent seropositivity rate
in the control group.  Most tumors were found in the limbus of 
the eye and the lesions in the HIV-infected patients were 
aggressive.  These findings are similar to those reported by 
Kesterlyn et al. from Rwanda, and suggest that in Uganda and its 
neighboring countries the recent increase in the frequency of 
conjunctival tumors is related to the HIV epidemic.  The human 
papillomavirus type 16 and ultraviolet light are also possible 
factors in the development of these cancers in equatorial Africa.
      
"Artificial Insemination by Donor"
Journal of the American Medical Association (03/15/95) Vol. 273, 
No. 11, P. 890;  Guinan, Mary E.
     The report of HIV infection in women who were artificially 
inseminated by donor represents another landmark in the history 
of HIV in North America, writes Dr. Mary E. Guinan in the Journal
of the American Medical Association.  Guinan, of the Office of 
HIV/AIDS at the Centers for Disease Control and Prevention (CDC),
discusses the experience of fertility clinics with high operating
standards in the early 1980s.  The clinics had requirements to 
screen semen donors for sexually transmitted diseases, which were
neither required nor standard practice at the time.  Now, 10 to 
14 years after seven women became infected through artificial 
insemination (AI), the procedure is safer.  The risk of 
transmitting HIV or any infection during AI by donor is very low.
Safety loopholes, however, still exist.  For example, AI 
practitioners are not required to register, and special training 
or licensing is not required, which makes it difficult to monitor
adherence to guidelines.  AI is safe but not completely so, 
concludes Guinan.  A woman who is informed, alert to the risk of 
HIV, and who insists that the semen donor be screened will 
increase the safety, Guinan adds.
      
